Abstract 111P
Background
Advanced stage colorectal cancer therapy shows positive progress by increasing overall survival (OS). Mainstay treatment still uses cytotoxic agents and oxaliplatin which results in an average survival of 18 months when combined with 5-Fluorouracil (5-FU) or capecitabine. This study aims to determine the effectiveness and safety of the use of FOLFOX and XELOX chemotherapy in advanced stage colorectal cancer patients using a meta-analysis study.
Methods
This is a meta-analysis study comparing only the Randomized Controlled Trial (RCT) study using FOLFOX and XELOX chemotherapy in patients with metastatic colorectal cancer taken from PubMed, EMBASE and The Cochrane Library using keywords: Capecitabine, FOLFOX, XELOX and metastatic colorectal.
Results
9 journals were included in the inclusion criteria and were followed by a meta-analysis study. A total of 5,873 patients were obtained with the number of groups given FOLFOX of 3,034 and 2,839 in the group given XELOX. The analysis doesn’t show evidence of publication bias in the forest plot. The results of the analysis of Progress Free Survival (PFS) found no significant heterogeneity (OR = 1.09, 95% CI: 0.97-1.23, p = 0.14), the Overall Survival (OS) analysis also did not obtain heterogeneity (OR = 0.98, 95% CI : 0.87-1.10, p = 0.77). Overall Response Rate (ORR) there were no significant differences in the two groups. All studies gave grade 3 and 4 toxicity. The results of the combined analysis showed thrombocytopenia, Hand Foot Syndrome (HFS) and diarrhea in the XELOX group were significantly higher.
Conclusions
The effectiveness of XELOX and FOLFOX found no significant differences. However, the safety of the XELOX group showed significantly more side effects. Keywords: FOLFOX, XELOX, Advanced Stage Colorectal Cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
24P - The Pink Vans: Bringing cancer screening closer to home
Presenter: Frederic Ivan Ting
Session: e-Poster Display Session
25P - Identification of gene mutations in patients with breast cancer in a region located in the southeast of the European part of Russia
Presenter: Alexander Sultanbaev
Session: e-Poster Display Session
26P - Body mass index and clinical outcomes in Egyptian women with breast cancer: A multi-institutional study
Presenter: Amrou Mamdouh Abdeen Shaaban
Session: e-Poster Display Session
27P - Breast cancer primary site and laterality as predictive factors of prognosis: SEER based analysis for survival
Presenter: Eman Zin Eldin
Session: e-Poster Display Session
28P - Breast cancer care services at Nilai Medical Centre: A Malaysian experience
Presenter: Ratnavelu Kananathan
Session: e-Poster Display Session
29P - Factors affecting breast self-examination (BSE) behaviour among female high school students in Denpasar City, Bali
Presenter: Cindy Trisina
Session: e-Poster Display Session
30P - Male breast cancer: A rural based peripheral cancer center experience
Presenter: SACHIN KHANDELWAL
Session: e-Poster Display Session
31P - The prognostic value of pre-treatment peripheral neutrophil-lymphocyte-ratio (NLR) and its correlation with mutant p53 expression in Indonesian triple negative breast cancer patients
Presenter: Rosita Purwanto
Session: e-Poster Display Session
32P - Clinicopathologic features and prognostic factors in male breast cancer: A single centre experience
Presenter: Izzet Dogan
Session: e-Poster Display Session
33P - FDG-PET predictivity of pathological axillary nodal status in carcinoma breast-upfront and post-neoadjuvant chemotherapy (NACT) setting
Presenter: Krithikaa Sekar
Session: e-Poster Display Session